Valvular & structural heart disease

Suture-Mediated Patent Fossa Ovalis Closure: Late Clinical Outcomes and Predictors of Technical Success

JACC AdvPublished cohort

Authors' conclusion

Suture-mediated PFO closure demonstrates long-term safety and efficacy. The LASSO score is a valuable tool for optimizing patient selection for this procedure.

Study context

Population
Patients with patent fossa ovalis (PFO)-associated stroke or transient ischemic attack undergoing suture-mediated PFO closureconsecutive patients, 2016–2023
Participants
703 patients
Outcome
Recurrent cerebrovascular events:
  • Stroke
  • Transient ischemic attack
Follow-up
Median clinical 4 years
Methodological detailsconsecutive patients
  • Consecutive patients

Main finding

As reported in the abstract

  • No recurrent cerebrovascular events (stroke or transient ischemic attack) were reported

Observational data: associations, not effects.

Further findings

Independent predictors of significant residual shunt (multivariable analysis)

EstimateP value
PFO maximum widthOR per 1 mm increase 1.34 (95% CI 1.19–1.50)P < 0.001
Minimum PFO lengthOR per 1 mm increase 0.92 (95% CI 0.86–0.98)P = 0.015
Atrial septal aneurysmOR 1.83 (95% CI 1.14–2.91)P = 0.011
Grade 3 Valsalva shuntOR 2.19 (95% CI 1.25–3.90)P < 0.007

Residual shunt · median transthoracic echocardiography follow-up time of 11.5 months

Among the 703 patients, showed residual shunt
91

Length, Aneurysm, Severe Shunt, Opening (LASSO) score discrimination (internal validation)

Area under the curve
0.73; 95% CI: 0.68-0.78
  • Internally validated

Safety

Atrial fibrillation · median clinical follow-up of 4 years

Transient episode of atrial fibrillation
1

Original publication

Suture-Mediated Patent Fossa Ovalis Closure: Late Clinical Outcomes and Predictors of Technical Success. JACC Adv. Published 11 July 2025. doi:10.1016/j.jacadv.2025.101991

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.